However, prostate tumor cells often develop resistance mechanisms that make them less sensitive to AR inhibition and more reliant on alternative pathways, such as the PI3K‐AKT–mTOR (PAM) signaling pathway. The gene discussed is PIK3CA; the disease is prostate neoplasm.